| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.024 | 0.6 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.6 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.6 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | necrostatin-7 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |